Screener
Cytokinetics CYTK Debt Repayments
Debt Repayments at other companies
Other financials
Where this comes from
Reported directly by Cytokinetics in its filing.
Tagged under the XBRL concept us-gaap:RepaymentsOfLongTermDebt.
The source filing: Cytokinetics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:30 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-338217
| Line item | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|
| Net cash (used in) provided by investing activities | (361,506) | 158,837 |
| Cash flows from financing activities: | ||
| Repayment of finance lease liabilities | — | (204) |
| Repayment of term loans | (6,329) | (5,378) |
| Payments of royalty obligations | (214) | — |
| Proceeds from RPI Transactions | — | 75,000 |
| Proceeds from issuance of common stock related to public offering, net of issuance costs | 760,149 | — |
| Proceeds from issuance of common stock under equity incentive and stock purchase plans | 49,348 | 14,396 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Cytokinetics's debt repayments?
- Cytokinetics (CYTK) reported debt repayments of $3.59M in Q2 2026.
- How has Cytokinetics's debt repayments changed year-over-year?
- Cytokinetics's debt repayments increased by 33.3% year-over-year, from $2.7M to $3.59M.
- What does debt repayments mean?
- Cash used to repay or retire outstanding debt obligations, including scheduled maturities and early redemptions.
Ask your AI about Cytokinetics's debt repayments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude